Issue link: http://osercommunicationsgroup.uberflip.com/i/265891
C h a i n D r u g s t o r e D a i l y M o n d a y, A p r i l 2 2 , 2 0 1 3 2 0 AMNEAL GROWS STRATEGICALLY IN INSTITUTIONAL, BIOSIMILAR AND INTERNATIONAL MARKETS In less than six years in the market, Amneal Pharmaceuticals has become the seventh largest generic drug manu- facturer in the U.S. with 109 million prescriptions dispensed each year, pro- duction capacity for oral solids that will soon reach 35 billion units annual- ly and nearly 240 ANDAs approved, filed or in development. Despite its phenomenal growth, this award-win- ning company remains passionate about continued expansion across its current business segments as well as into new products, dosage forms and markets, all while maintaining its total commitment to quality and superior customer value and relationships. Amneal is now extending its philos- ophy to the institutional market with the creation of Amneal Institutional (AI)―a business unit dedicated to generic prod- ucts and packaging designed to meet the specific needs of health systems, clinics, and physicians' offices. With an average of more than 25 years in the pharmaceutical industry, AI's account management team has extensive experi- ence serving the institutional market, widely defined as hospitals and other acute care facilities, outpatient surgical and radiology services, oncology cen- ters, home infusion service providers, long-term care centers, correctional facilities, specialty pharmacies, and group purchasing organizations. Amneal Institutional's product selection includes sterile injectables in a variety of device formats and unit- dose packaging of the oral solids on which the generic maker's stellar repu- tation was built. Some of the near-term launch products are on the U.S. FDA Drug Shortage List and should help address current market supply issues. There are several other products expected to be approved and launched through year-end as well as a robust pipeline for 2014 and beyond. Understanding the strategic direc- tion of the industry, Amneal began moving into biologicals in 2009 and expanded into biosimilars with the early 2012 acquisition of Therapeutic Proteins International (TPI), a biosimi- lars development firm in Chicago. TPI's management team offers exten- sive, industry-wide experience in this rapidly evolving area of pharmaceuti- cals, in both the domestic and interna- tional markets. The company's revolu- tionary patented disposable bio-reac- tor-based manufacturing technology radically alters biological production paradigms, enabling superb quality manufacturing and accelerated time-to- market. TPI is focused on developing five initial products with the first FDA approval anticipated in 2014. Prolong Pharmaceuticals, the biologicals firm acquired in 2009, is developing biobet- ters using PEGylation technology invented by its chairman. Finally, Amneal is exploring markets outside the U.S. where it can expand strategically. For the past several years, the company has carefully evaluated opportunities in each international sector to identify smart ways to grow its gener- ics business, whether organically or through acquisitions and partnerships. Even as it develops a global reach, Amneal is committed to an unwavering focus on serving the U.S. market, the foundation of its generic pharmaceuticals business and the reason for its success. Visit Amneal at meeting space 218 at the NACDS Annual Meeting, go online to www.amneal.com or call the company at 866-525-7270. CROSSMARK MPG DRUG DELIVERS ACTIONABLE INSIGHTS FOR RETAILERS, MANUFACTURERS IN DRUG CHANNEL An increasing number of retailers and manufacturers in the drug channel are looking for the best ways to leverage shopper data. But making the data action- able is not always easy. Drawing on one of the industry's leading business insights teams, CROSSMARK MPG Drug provides data insights that drive revenues and profits for clients and retail- ers and create more enjoyable shopper experiences for the consumer. "Business analytics, including store and consumer-specific targeting and seg- mentation, help retailers and manufactur- ers make better decisions regarding assortments, adjacencies, promotional planning, pricing and targeted marketing support," said Tim Bennett, Vice President, CROSSMARK MPG Drug. As a division of CROSSMARK, a leading sales and marketing services company in the consumer goods industry, CROSSMARK MPG Drug has access to proprietary analytics with store-level data from the company's Business Insights group using data from The Nielsen Company, Symphony IRI and other sources. In addition, CROSS- MARK works with clients to analyze and provide insights on retailer-specific loy- alty card data. CROSSMARK MPG Drug is the largest provider of head- quarter sales and retail services in the U.S. drug channel. "We provide inte- grated, end-to-end capabilities to ensure seamless execution of a strong plan," Bennett said. Bennett joined CROSSMARK MPG Drug earlier this year and now, with Vice President of Business Development Alex Yakulis, leads the division by creating strategies and delivering results in the drug channel. Yakulis said retailer, shop- per and industry data are just part CROSSMARK MPG Drug's deep knowledge of the drug channel. "CROSSMARK MPG Drug is known for providing its clients with the best solutions for greater performance in the drug channel," Yakulis said. "Our strong market analytics capabili- ty―combined with headquarter and in-store execution in the drug chan- nel―makes us a great partner for devel- oping important insights. According to Yakulis, CROSS- MARK MPG Drug knows what it takes from both a retailer and manufacturer perspective to be successful. "Our rela- tionships and expertise across all major drug chains provide insights that help us drive effective growth strategies for our clients." CROSSMARK MPG Drug provides manufacturers a range of solutions including insights and analytics, cus- tomer planning, headquarter sales sup- port and in-store execution. Retailer solu- tions include management of coordinated merchandising programs, category resets and in-store events such as product demos and sampling. For more information, contact Alex Yakulis at 469-814-1434 or alex.yakulis@crossmark.com. CATALINA HEALTH SPEARHEADS PATIENT MEDICATION INFORMATION QUALITY IMPROVEMENT INITIATIVE In an ongoing effort to improve adher- ence and to strive towards healthier out- comes, Catalina Health ® launched an eight-week quality improvement (QI) initiative, with other health care partners, to disseminate newly designed patient medication information (PMI) to patients filling prescriptions at pharmacies. The new PMI was distributed in a leading pharmacy chain in California and Michigan for three medications. The results show more than 90 percent of patients recalled receiving the new patient information and considered the written information useful. The goal of the QI initiative was to provide patients with clearer medication information when they pick up prescrip- tions at the pharmacy. Through voluntary telephone and online responses, patients were surveyed to confirm they received the new PMI, assessed whether they found the information useful, and deter- mined how they would like to receive this newly formatted patient medication information in the future. Survey results revealed the follow- ing: Females and males had an equally high recall rate (more than 90 percent) of receipt of the single-page PMI docu- ment, all age groups from 18-65-plus years old had an equally high recall rate of receipt of the single-page document (more than 90 percent), more than 65 percent of females and males read the information, new patients were more likely to not only read, but also keep PMI, more than 90 percent of all patients found PMI useful, patients ages 18-40 would prefer to have PMI deliv- ered electronically in addition to receiv- ing the single-page PMI in the pharma- cy, and Patients of all age groups prefer to have a pharmacist explain the PMI along with receiving a written document. "This eight-week project demon- strates that patients want, read, and keep a single page of information about their prescriptions that is written in an easy to understand format, rather than multiple pages of complex medical text," said Renee Selman, Catalina Health President. "Catalina Health is committed to providing patients clearer information, and we are proud to have led this pharmacy pilot with our health care partners." In 2008, Catalina Health was one of the groups that spearheaded a citizen's petition urging FDA to improve the infor- mation patients receive. Based on efforts the Food and Drug Administration has taken, the citizen petition was withdrawn to allow this quality improvement initia- tive to proceed. "The FDA commends these organi- zations for their efforts to study ways to best provide the important information that patients need to take their medicines safely," said Janet Woodcock, M.D., Director of the Center for Drug Evaluation and Research at the FDA. According to the company, Catalina Health is committed to helping its part- ners deliver unprecedented performance and healthier outcomes for their health consumers. Fueled by its powerful insights and unique access to 130 million health consumers, Catalina Health's mul- tichannel approach is designed to facili- tate the delivery of personalized and rel- evant messages at critical points of care along the Health Consumer Journey ® , which includes the pharmacy, the doc- tor's office and home. For more information, visit table 268 at the NACDS Annual Meeting or contact Harry Musumeci, Group Director, Business Development at 215-793-3813 and harry.musumeci@catalinamarketing.com.